Revolution Medicines (RVMD) Receivables (2020 - 2023)

Revolution Medicines has reported Receivables for 4 years, with the latest figure at $1.3 million in Q4 2023.

• For the quarter ending Q4 2023, Receivables fell 73.16% year-over-year to $1.3 million; the trailing twelve-month figure through Dec 2023 stood at $1.3 million (down 73.16% YoY), and the FY2023 full-year result was $1.3 million, down 73.16% from the prior year.
• Receivables for Q4 2023 stood at $1.3 million, up from $309000.0 in the prior quarter.
• The five-year high for Receivables was $12.8 million in Q4 2020, with the low at $309000.0 in Q3 2023.
• Average Receivables over 4 years is $5.3 million, with a median of $5.4 million recorded in 2022.
• Year-over-year, Receivables declined 13.83% in 2022 and plunged 93.74% in 2023.
• Tracing RVMD's Receivables over 4 years: stood at $12.8 million in 2020, then tumbled by 53.63% to $5.9 million in 2021, then declined by 21.18% to $4.7 million in 2022, then sank by 73.16% to $1.3 million in 2023.
• The last three Receivables figures came in at $1.3 million (Q4 2023), $309000.0 (Q3 2023), and $2.5 million (Q2 2023), per Business Quant data.

Peer Comparison